Approach to Bipolar Disorder

Dr. Jon Davine, MD, FCFP, FRCP©





Presenter Disclosure

Presenter: Dr. Jon Davine MD, FCFP, FRCP©

Relationships with financial sponsors:

- Any direct financial relationships, including receipt of honoraria: Trillium Health Partners, William Osler Health System, Peterborough FHT, Pri-Med Canada/Humber R. Hosp., McMaster U. CE, KW Family Medicine, Ont. Coll. Of Family Phys., Touchstone Institute, CME Away by Sea Courses
- Membership on advisory boards or speakers' bureaus: No
- Patents for drugs or devices: No
- Other: CAMH, Co-Editor of book, "Psychiatry in Primary Care"

Disclosure of Financial Support

This program has not received financial support

This program has not received in-kind support

Potential for conflict(s) of interest:

Dr. Jon Davine has not received payment/funding for this program



Objectives

- Learn how to make the diagnosis of bipolar in a time efficient manner
- Learn how to use psychopharmacology to treat Bipolar Disorder, using current guidelines
- Learn about issues of psychopharmacology and pregnancy

Bipolar Disorder

• MANIC

- 7 days or more, unless hospitalized
- Interferes with life greatly
- Increased mood
- Increased energy
- Decreased sleep

• HYPOMANIC

- 4 days or more
- Somewhat interferes with life, seen by others as uncharacteristic
- Same features as manic, no marked impairment in functioning

Bipolar Disorder

- IMPORTANT: <u>Separate Bipolar II from Axis</u> II, cluster B mood lability
 - Remember time line, days vs. hours or a day
 - Out of the blue vs. response to stressors

Bipolar I vs. Bipolar II

Bipolar I

- Manic phase(s) +/- depression phase(s)
- 1% lifetime prevalence

Bipolar II

- Hypomanic phase(s) + depression phase(s)
- 1.1% lifetime prevalence

Cyclothymic

- 2 years, numerous episodes
- Does not meet criteria for hypomanic or depression
- Present at least half the time
- Impairs functioning

• Overall, 2-3% lifetime prevalence Bipolar Spectrum

Bipolar Disorder

- Mean age of onset early to mid 20's
 - Peak age is 15-19
- Initially
 - Depression in women
 - Mania in men
- Twin studies and first degree relative studies support the fact of heritability



Bipolar Terms

Bipolar

- Manic phase
- Hypomanic phase
- Depressed
- Mixed phase depression and mania essentially coexist, switching over hours, or every 1 - 2 days. Also has been called ultra rapid cycling. Must last at least one week. Causes marked impairment in functioning.

Rapid Cycling

- 4 or more episodes/year
- Going from manic to depressed counts as two episodes

THINGS TO DO:

- Assess for organicity
- Harm to others (e.g., driving)

EtOH/Substance abuse

- High co-morbidity rate
- Can worsen

Suicidality

- 17-19% lifetime prevalence of completed suicide
- More often in depressed state

Acute Treatment of Mania

- Acute treatment duration = 2 to 10 weeks
- Rule out organic
 - Cushing's
 - Thyroid
 - MS
 - Steroids
 - *antidepressants controversy
 - Substance abuse

Psychoeducation

Educate:

- Inadequately treated patient may have 10 or more episodes
- Intervals between episodes narrows as person ages
- Sleep deprivation can provoke hypomanic/mania

Levels of Evidence

- Level 1
 - Meta-analysis or replicated RCT with placebo
- Level 2
 - At least one RCT with placebo or active comparison condition
- Level 3
 - Uncontrolled trial with 10 or more subjects
- Level 4
 - Anecdotal reports or expert opinion

Treatment Recommendations

- 1st line (A)
 - Level 1 or 2 evidence plus clinical support for efficacy and safety
- 2nd line (B)
 - Level 3 evidence or higher plus clinical support for efficacy and safety
- 3rd line (C)
 - Level 4 evidence or higher plus clinical support for efficacy and safety
- Not Recommended
 - Level 1 or 2 evidence for lack of efficacy

• (CANMAT 2018 Bipolar Guidelines)

Lithium – Indications for 3 Phases

Anti-manic (A)

- 78% response rate
- Level I evidence,

Anti-depressant (A)

- 79% response rate
- Level I evidence,

Prophylaxis

- (**is** (A)
- 6 fold decrease in subsequent episodes
- Level I evidence,



Lithium – What to do before starting:

- Workup repeat every 6-12 months
 - ECG
 - CBC
 - TSH
 - Creatinine, 'lytes, u/a
 - Ca
 - Pregnancy test if applicable

Lithium – follow up

Blood lithium levels

• 12 hour trough

- 5-7 days after starting, and then 5-7 days after dosage changes
- Get 2 therapeutic serum levels, then repeat q3-4 months.

Lithium – Pharmacology

- Half-life = 14-30 hours
- Not metabolized
 - Cleared by kidney (mind renal function)
 - Not protein bound

Lithium – Side Effects

- Polyuria, polydipsia (Diabetes Insipidus)
 - Treat with diuretics if necessary
- * Increase weight
- Cognitive problems
- * Tremor
 - Treat with Beta-Blockers
- Sedation
- * GI distress
- Increase WBC
- ECG changes
 - Usually benign
 - Rarely conduction abnormality

Lithium – Other Effects

- Hypothyroid (5-35%)
 - More females after 6-18 month treatment
 - Generally reversible
 - Can replace with thyroxine
- Nephrotoxicity

Lithium – Levels and Side Effects

- 0.4-0.6 mmol/L
 - Decreased side effects
 - Increased risk of episodes
- 0.6-0.8 mmol/L
 - Most often chosen
 - Not well studied
- 0.8-1.1 mmol/L
 - Deceased risk of episodes
 - Increased side effects
- Balance must be chosen between efficacy and side effects

Lithium – Overdose

• >1.5 mmol/L = Toxic

- coarse tremor
- Vomiting
- Blurred vision
- Vertigo
- Confusion
- Increased DTR

• > 2.5 mmol/L = Life threatening

Treatment: hemodialysis

Lithium - Dosage

- Start at 300 mg PO BID
- Increase by 300 mg/day depending on levels
- Usual dosage 900-1500 mg/day
- Geriatric: Start at 150 mg. po od, and increase by 150 mg. increments
- Measure "trough" levels
 - Patient to have blood test 12 hours post last dose

Valproic Acid – Indications

- Manic 56% response rate (near Lithium effectiveness)
 - Level I evidence (A for mania and mixed states)
- Bipolar Depression Few studies for bipolar depression
 - Level III evidence (B)
- Prophylaxis
 - Level II evidence (A)

Valproic acid - Pharmacology

- 2 forms
 - Valproate and Divalproex sodium
 - Divalproex sodium (Epival) has less GI side effects, and is therefore preferred
- Half-life = 6-16 hours
- Metabolized by liver
- Protein bound

Valproic Acid – Side Effects

- * GI distress (use divalproex sodium)
- Sedation
- * Benign increased ALT, increased AST
- Tremor
- Hepatotoxicity
- Decreased platelets, WBC
- *Increased appetite, weight
- Agranulocytosis
- Polycystic ovarian disease contraindicated

Valproic Acid – When you start:

- Workup before starting
 - History And Physical
 - LFT'S
 - CBC with platelets
 - Do initially, then at 4 weeks, repeat q 3-6 months
- Starting Dose 250 mg BID.
 - Increase by 250 mg Increments weekly
 - Geriatric: Start at 125 mg. po od, and increase by 125 mg. increments
- Levels
 - 350-700 µmol/L3

Lamotrigine – Indications

- Mania
 - Level III evidence (D)
- Depression
 - Level I evidence (A)
- Prophylaxis
 - Level I evidence (A)

Lamotrigine

- Especially helpful from down-up
 - More effective in preventing depression
- Less weight gain
- Watch for any rash (about 5%)
- Severe rash 3/1000
- Stevens-Johnson syndrome a possibility, (1/1000), thus D/C.
- Start at 12.5-25 mg PO OD
- Increase by 12.5-25 mg PO q1-2weekly
- Levels Usually 50-200 mg/day
 - No blood level monitoring necessary

Lamotrigine, Bipolar 2, Depressed Phase

- Family docs may be the first ones to make this diagnosis
- Always screen for hypomania when someone presents with a SIGECAPS depression
- Lamotrigine is approved for bipolar prophylaxis— Level 1A
- It is also Level 1A for bipolar depression. "2 birds..."
- It has less weight gain. People love this.

Gabapentin, Topiramate

- For mania, depression, and prophylaxis:
 - Level III (D)
- Not recommended or proscribed

CANMAT 2018: 1st Line Mania

- Lithium
- Quetiapine
- Divalproex
- Asenapine
- Aripiprazole
- Paliperidone (>6 mg.)
- Risperidone
- Cariprazine

All Level 1

CANMAT (2018) First line combination, Acute Mania

Quetiapine + Li/DVP Aripiprazole + Li/DVP Risperidone + Li/DVP Asenapine + Li/DVP

Level 1 Level 2 Level 1 Level 2

Atypical Neuroleptics

- Risperidone, Olanzapine, and Quetiapine are all approved for use as anti manic agents
- Risperidone--1-4 mg/day
- Olanzapine 5-20 mg/day
- Quetiapine 200-800 mg/day
- Aripiprazole 10 -15 mg/day
- Ziprasidone 20-80 mg BID
- Anti-manic, anti-psychotic

Bipolar Depression

- 20% of Bipolar Depressive Episodes run a chronic course
- Mild depressive symptomatology may be successfully treated with CBT or IPT
- Lithium
 - Response rates from 64% to 100%. Level I (A) evidence

Antidepressants

- Level I (B) evidence.
- Watch for flips (more common with tricyclics)
- Use with concomitant mood stabilizer to avoid flips



Lamotrigine in Bipolar Depression

- Lamotrigine
- Level 1(A)
 - Sometimes added to lithium as mood stabilizer
 - It works better from the "bottom up"
 - Lithium and Epival work better from the "top down"



1st Line for Depression (2018 CANMAT)

- Quetiapine Level 1
- Lurasidone + Li/DVP
- Lithium
- Lamotrigine
- Lamotrigine (adj)

Level 1 Level 2 Level 2 Level 2

2nd line Depression (CANMAT 2018)

- Divalproex Level 2
- SSRI's/Buproprion (adj) Level 1
- ECT Level 3
- Cariprazine Level 1
- Olanzapine-Fluoxetine Level 2

Atypical Neuroleptics in Bipolar Depression

- •Quetiapine now approved for bipolar depression (CANMMAT)
- •Level 1(A) evidence
- •Also level 1(A) for mania and prophylaxis
- •Recommend do metabolic screens q4monthly when on Quetiapine.
- •LFT's as hepatic metabolized

Continuation Phase of Treatment

- Continue with psychoeducation/counseling
 - Develop relationship
 - Helps compliance with meds—Very Important
 - Stay off Alcohol and drugs—Very Important
 - Deal with stressors—Stress Diathesis model applies

Drugs in Continuation Phase

- If Benzos were used, try to wean off
 - No evidence for them as prophylactic agents
- If Atypical Neuroleptics were used, gradually wean and discontinue after 2-3 months of stability, **unless**:
 - Being used as mood stabilizer (Quetiapine XR)
 - persistent psychosis (schizoaffective disorder)

CANMAT (2018)1st line,

Propylaxis

- Lithium
- Quetiapine
- DVP
- Lamotrigine
- Asenapine
- Quetiapine + Li/DVP
- Aripiprazole +Li/DVP
- Aripiprazole
- Aripiprazole (OM)

- Level 1 Level 1 Level 1 Level 1 Level 2
- Level 1 Level 2 Level 2
 - Level 2

Therapy in Pregnancy

- All mood stabilizers are teratogenic
 - Risk vs. benefit
- Lithium lower risk (Ebstein's anomaly, 0.1%)
 - Tricuspid valve displacement
- If illness not that severe, consider planned pregnancy without meds
 - 4 week medication-free period pre-conception
- ECT, SSRI, Neuroleptics all lower risk in 1st trimester



Epival in Pregnancy

- Epival (sodium valproate) much more problematic
 - Neural tube defects may increase to 5%
 - Try to avoid in women of child bearing age, especially weeks 1-10.
- Can use folic acid 5 mg. PO OD
- Can do serial ultrasounds examining the neural tube



Lamotrigine in Pregnancy

- Cleft lip and palate
- Possible less teratogenic


Dosage in Pregnancy

- Post partum has >50% risk of an episode
 - Recommend re-start therapy after delivery
- All secreted through breast milk
 - Data suggests no immediate risk
 - No data regarding later behavioural effects

Disability Issues

- Stable bipolar is not disabling
 - Most people should hit their normal "life arc", including working
 - Let patients know this!
- A minority of treatment resistant cases may require disability







FamilyMedicineForum



FamilyMedForum



FamilyMedForum